RESULTS REVISE AND UPDATE DONG YING Q3 RESULTS REPORTED DECEMBER 10, 2008
NANTONG CITY, China, Jan. 29 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. is pleased to report financial highlights from the complete unaudited financial results of its wholly owned operating subsidiary, Dong Ying China, that have been consolidated into Sinobiopharma’s financial statements for the six-month period ended November 30, 2008. The complete unaudited financial results for the period were filed with the SEC in Form Q10 on January 14, 2009 and available at www.edgar-online.com.
Financial highlights include:
Mr. Lequn Huang, Chairman and CEO of Sinobiopharma Pharmaceutical Group, commented: “Sinobiopharma achieved significant year-over-year growth in the six months ending November 30, 2008 in both sales and gross margin. As we move forward in early 2009, we will continue to focus on building our portfolio of innovative and first-to-market drugs through organic growth and acquisitions. We also plan to enhance our investment in sales and marketing activities to help Sinobiopharma achieve sustainable, long-term growth.”
About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD-LOOKING STATEMENTS
This news release may include “forward-looking statements” regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
CONTACT: Investor Relations, Sinobiopharma, Inc., 1-877-568-0188
Web site: http://www.sinobiopharma.com/
